Expression of HUVEC ADAMTS13 compared with HUVEC VWF
| cDNA . | Ct . | ΔCt . | Ratio of ADAMTS13 to VWF . |
|---|---|---|---|
| 10 ng | 107-fold lower | ||
| ADAMTS13 | 29.83 ± 1.33 | 7.4 ± 1.93 | |
| VWF | 22.43 ± 2.29 | ||
| 2 ng | 142-fold lower | ||
| ADAMTS13 | 29.2 ± 1.36 | 7.85 ± 1.56 | |
| VWF | 21.34 ± 1.45 |
| cDNA . | Ct . | ΔCt . | Ratio of ADAMTS13 to VWF . |
|---|---|---|---|
| 10 ng | 107-fold lower | ||
| ADAMTS13 | 29.83 ± 1.33 | 7.4 ± 1.93 | |
| VWF | 22.43 ± 2.29 | ||
| 2 ng | 142-fold lower | ||
| ADAMTS13 | 29.2 ± 1.36 | 7.85 ± 1.56 | |
| VWF | 21.34 ± 1.45 |
Expression of HUVEC ADAMTS13 and VWF mRNA was quantified by real-time PCR. The data are generated from the difference in threshold cycle (Ct) for each gene amplified from either 2 ng or 10 ng of cDNA. The fold difference in expression was calculated (after normalizing to glyceraldehyde-3-phosphate dehydrogenase) by the equation: fold difference = efficiencyΔCt. RNA was extracted and reverse-transcribed, and the resulting cDNA was amplified in triplicate in 5 separate experiments.